26
Mar
2020
Adjusting to Telemedicine: A First-Hand Account
One consequence of the present crisis is the urgent embrace of telemedicine, as I recently discussed. Whether the adoption is sustained beyond the crisis period remains to be determined, although use seemed to be increasing overall even before the pandemic hit. As more physicians and patients find themselves pressed to adopt telemedicine, I thought it might be helpful to better... Read More
26
Mar
2020
The Coronavirus Tsunami, Lyell’s $492M Megaround & Some Deals You Missed
When a story moves with exponential speed and deadly force, it’s hard for a human being to keep up. Hard for you, and hard for me. My approach these past few weeks has been to work with purpose and passion on this story that touches all of humanity. The plan has been to seek out diverse voices with fresh perspectives... Read More
26
Mar
2020
Pharmacy as the Biomarker of Biopharma’s Strategic Change, After Coronavirus
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Mar
2020
We Interrupt This Nightmare to Bring You a Few Giggles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.